Home › Cancer (all types) › NCT05697406

HP Pyruvate MRI in Cancers

Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers

Who can join

Ages 18 to 88 · All sexes

Inclusion Criteria:

Clinical tumor diagnosis

Patients with pre-existing MR imaging appointments

Must be able to undergo MR

Exclusion Criteria:

No tumor diagnosis

About the study

Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.

What is being tested

• Hyperpolarized 13C-Pyruvate (drug)

Sponsor: University of Maryland, Baltimore · Participants: 25 · Started: Jun 24, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT05697406

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.